1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from May to August 2022:
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Faricimab
Ranibizumab – Lucentis
Ranibizumab – Ongavia
2. Please provide the number of injections/implants by eye condition for the four-month period from May to August 2022.
Eye Conditions
Wet Age-Related Macular Degeneration wAMD
Diabetic Macular Degeneration DMO
Retinal Vein Occulusion RVO
Treatment
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Faricimab
Ranibizumab – Lucentis
Ranibizumab – Ongavia
